TAIPEI (Taiwan News) — Adimmune Corp. will launch its enterovirus vaccine in Vietnam by the end of next year, marking its first entry into the Southeast Asian market for this vaccine.

Adimmune Chair Steve Chan (詹啟賢) said the company’s Taichung cell culture plant has received Thailand’s Good Manufacturing Practice certification, paving the way for the expansion of its enterovirus vaccine into Southeast Asia, CNA. 

Adimmune’s flu vaccines supply nearly half of Taiwan’s government-funded doses and are exported to Southeast Asia and Eastern Europe. The company’s flu vaccine facility is also certified under Brazil’s GMP standards, Chan noted.

In September, the World Health Organization added the company’s influenza, tetanus, and enterovirus vaccines to its list of vaccine products, a move expected to boost Taiwan’s global presence in the medical field. The company’s tetanus vaccine is the only one of its kind in Taiwan to be included in the WHO's list, with an annual supply exceeding one million doses. 

Chan said the company has also developed a new single-dose tetanus injection, expected to be available by the end of this year. Additionally, its enterovirus 71 vaccine has completed the third phase of clinical trials, with data showing 99.21% efficacy.

Adimmune said that it signed an agreement last year with the WHO to receive virus strain information immediately during a new influenza outbreak, allowing it to speed up the development of vaccines and antiviral drugs.

The company posted NT$656 million (US$21.2 million) in revenue for the first three quarters of this year, with a net loss of NT$194 million. Following continued international production orders and upgrades to its facilities and production lines, the company expects fourth-quarter revenue to turn profitable.

Chan added that Adimmune’s domestic sales made up more than 60% of revenue in 2020, but since 2022, exports have accounted for over 60%, with the company’s market spanning the US, China, Japan, Europe, and Southeast Asia.